Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

Pharmacogenetics - 1 Jun 2004

Hughes Dyfrig A, Vilar F Javier, Ward Charlotte C, Alfirevic Ana, Park B Kevin, Pirmohamed Munir

Abstract excerpt

OBJECTIVE: Abacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue reverse transcriptase inhibitor, causes severe hypersensitivity in 4-8% of patients. HLA B*5701 is a known genetic risk factor for abacavir hypersensitivity in Caucasians. Our aim was to confirm the presence of this genetic factor in our patients, and to determine whether genotyping for HLA B*5701 would be a cost-effective use of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monte Carlo Method
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dideoxynucleosides

Share to Drug Hypersensitivity

Share to HLA-B Antigens

Share to Molecular Diagnostic Techniques

Share to Point-of-Care Systems

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 15247625
DOI: 10.1097/00008571-200406000-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.PMID 15247625Read ↗

HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.Semantic proximity Read ↗

Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescriptionSemantic proximity Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in SpainSemantic proximity Read ↗

A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.Semantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience.Semantic proximity Read ↗

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Semantic proximity Read ↗

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.Semantic proximity Read ↗

HLA-B*5701 testing to predict abacavir hypersensitivitySemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

Successful translation of pharmacogenetics into the clinic: the abacavir example.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.